SOBI to market Xiapex in EU and other countries

Auxilium Pharmaceuticals, and Swedish Orphan Biovitrum AB (SOBI) have entered into a long-term collaboration for the development, supply and commercialization of Xiapex (collagenase clostridium histolyticum), for the treatment of Dupuytren's contracture. In addition, work is on-going to file for approval of Xiaplex for the treatment of Peyronie's disease in the EU. SOBI will receive exclusive rights to commercialize Xiapex for these two indications, subject to applicable regulatory approvals, in 28 EU member countries, Switzerland, Norway, Iceland, 18 Central Eastern Europe/Commonwealth of Independent countries, including Russia and Turkey, and 22 Middle Eastern & North African countries.